hello@apconix.com

Alleviating the Long-term Cardiotoxicity of Cancer Therapies

Alleviating the Long-term Cardiotoxicity of Cancer Therapies Kimberly Rockley completed her PhD in the Division of Pharmacy at Durham University before joining us at ApconiX in June last year. Her research utilised in vitro cardiomyocyte models to investigate the link between angiotensin signalling and anthracycline-induced cardiotoxicity. Here she describes [...]

By |2021-08-12T15:39:04+01:00January 16th, 2020|Toxicology|Comments Off on Alleviating the Long-term Cardiotoxicity of Cancer Therapies
Read More

Preclinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”

Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients. Dr Richard Knight of Alderley Park-based ApconiX told last month’s conference, Accelerating Cancer Drug Development – from target to patients, that greater focus on pre-clinical safety should be fundamental to [...]

By |2021-11-30T13:02:38+00:00March 27th, 2018|Toxicology|Comments Off on Preclinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”
Read More
Copyright ApconiX | All Rights Reserved | Website by Greenlight Web
Go to Top